Quince Therapeutics Inc (NASDAQ:QNCX)’s traded shares stood at 0.65 million during the last session, with the company’s beta value hitting 0.81. At the close of trading, the stock’s price was $1.43, to imply an increase of 19.17% or $0.23 in intraday trading. The QNCX share’s 52-week high remains $2.45, putting it -71.33% down since that peak but still an impressive 64.34% since price per share fell to its 52-week low of $0.51.

Quince Therapeutics Inc (NASDAQ:QNCX) trade information

After registering a 19.17% upside in the last session, Quince Therapeutics Inc (QNCX) has traded red over the past five days. The 5-day price performance for the stock is 22.22%, and 69.95% over 30 days. With these gigs, the year-to-date price performance is -23.53%.

An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 7.53% for the past 5-year period. While 2025 is set for a 25.95% return in earnings, projections for the next 5 years are at 25.46% annually.

QNCX Dividends

Quince Therapeutics Inc has its next earnings report out in July. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

We also have VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Quince Therapeutics Inc (QNCX) shares. Going by data provided on Mar 31, 2025 , VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund holds roughly 861.39 shares. This is just over 1.89% of the total shares, with a market valuation of $1.23 million. Data from the same date shows that the other fund manager holds a little less at 418.22, or 0.92% of the shares, all valued at about 0.6 million.